Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Jan Wehkamp
PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data from UNIFI Study of Stelara Presented at ECCO
In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Disease Area Leader, Gastroenterology at Janssen Research & Development shared his views on the data regarding the safety & efficacy of Stelara (ustekinumab) for UC patients, including long-term symptomatic & corticosteroid-free remission rates from the UNIFI study. Shots: The P-III UNIFI study evaluates the safety & efficacy…
August 9, 2021
Viewpoints_Laurent Debussche
PharmaShots Interview: Sanofi’s Laurent Debussche Shares Insight on the Need of SERDs for ER+ Breast Cancer
In an interview with PharmaShots, Laurent Debussche, Global Head of Molecular Oncology Research Therapeutic Area at Sanofi shares insight on the SERDs data being presented at ASCO 2021 and highlight the need for this type of innovation for ER+ breast cancer Shots: Sanofi has presented the data from P-I AMEERA-1 study evaluating amcenestrant in combination with palbociclib &…
August 9, 2021
Viewpoints_Kelly Pokuta and April Kunze
PharmaShots Interview: Prime Therapeutics’ Kelly Pokuta and April Kunze Share Insight on Medical Drug Management Program
In an interview with PharmaShots, Kelly Pokuta, Vice President of Pharmaceutical Trade Relations, and April Kunze, Senior Director, Clinical Formulary Development & Trend Management Strategy at Prime therapeutics share their views on the MedDrive as a first-of-its-kind medical drug management program uniquely aligned with Blue Plan clients. Shots: Prime introduced the first-of-its-kind medical drug management…
August 3, 2021
Viewpoints_Bassil I. Dahiyat
PharmaShots Interview: Xencor’s Bassil I. Dahiyat Shares Insight on the US FDA’s Approval of COVID-19 Antibody Treatment Leveraging its Technology
In an interview with PharmaShots, Dr. Bassil I. Dahiyat, President and CEO of Xencor shared his views on the company's collaborations with BMS and its Xtend XmAb technology. He also shed light on the EUA of Sotrovimab for COVID-19. Shots: The FDA has granted EUA to Vir and GSK's sotrovimab, which was engineered with Xencor's XmAb…
August 3, 2021
Viewpoints_Dr. Lotus Mallbris
PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insight on the Data of Taltz and Olumiant Presented at EULAR 2021
In an interview with PharmaShots, Dr. Lotus Mallbris, M.D., Ph.D., Vice President of Immunology Development at Lilly shared her views on the abstracts demonstrating data on the use of Taltz and Olumiant in rheumatic diseases, including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) for Taltz, and rheumatoid arthritis (RA) for Olumiant.  Shots: Lilly reported that key data from Taltz (ixekizumab) & Olumiant (baricitinib) is highlighted at the virtual EULAR…
August 2, 2021
Viewpoints_Justin Odegaard
PharmaShots Interview: Guardant Health’s Justin Odegaard Shares Insight on the US FDA’s Approval of Guardant360 CDx for Amgen’s Lumakras
In an interview with PharmaShots, Justin Odegaard, Vice President of Clinical Development at Guardant Health shares his views on the Guardant360 CDx approval as the first & only liquid biopsy companion diagnostic for Amgen's Lumakras (sotorasib) KRASG12C inhibitor for use in advanced NSCLC. Shots: Guardant Health received the US FDA's approval for Guardant360 CDx liquid biopsy for use in conjunction…
July 29, 2021
Viewpoints_Dr. Krishnansu S. Tewari and Israel Lowy
PharmaShots Interview: Dr. Krishnansu S. Tewari and Israel Lowy Share Insight on P-III Data of Libtayo Presented at ESMO Virtual Plenary
In an interview with PharmaShots, Krishnansu S. Tewari, Professor and Director of the Division of Gynecologic Oncology at the University of California, and Israel Lowy, Senior Vice President, Translational and Clinical Sciences, Oncology at Regeneron share their views on the data of Libtayo in cervical cancer patients, presented at ESMO Virtual Plenary. Shots: Regeneron and Sanofi reported…
July 28, 2021
Viewpoints_Dr. Andrew Krivoshik
PharmaShots Interview: Astellas’ Dr. Andrew Krivoshik Shares Insights on P-II FAST Study of Zolbetuximab
In an interview with PharmaShots, Dr. Andrew Krivoshik, Senior Vice President and Oncology Therapeutic Area Head at Astellas, shared his views on the P-II FAST study result published in the journal Gastric Cancer and highlights the data published in Annals of Oncology. Shots: The data from P-II FAST study evaluating zolbetuximab + EOX in 1L patients with advanced gastric and…
July 26, 2021
Load more